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Vignette-Based Utilities: Usefulness, Limitations, and Methodological
Recommendations
Louis S. Matza, PhD, Katie D. Stewart, MA, Andrew J. Lloyd, DPhil, Donna Rowen, PhD, John E. Brazier, PhD
A B S T R A C T
Health technology assessment agencies often prefer that utilities used to calculate quality-adjusted life years in cost-utility
analyses (CUAs) are derived using standardized methods, such as generic preference-based measures completed by pa-
tients in clinical trials. However, there are situations when no standardized approach is feasible or appropriate for a specific
medical condition or treatment that must be represented in a CUA. When this occurs, vignette-based methods are often used
to estimate utilities. A vignette (sometimes called a “scenario,” “health state description,” “health state vignette,” or “health
state”) is a description of a health state that is valued in a preference elicitation task to obtain a utility estimate. This method
is sometimes the only feasible way to estimate utilities representing a concept that is important for a CUA. Consequently,
vignette-based studies continue to be conducted and published, with the resulting utilities used in economic models to
inform decision making about healthcare resource allocation. Despite the potential impact of vignette-based utilities on
medical decision making, there is no published guidance or review of this methodology. This article provides recommen-
dations for researchers, health technology assessment reviewers, and policymakers who may be deciding whether to use
vignette-based methods, designing a vignette study, using vignette-based utilities in a CUA, or evaluating a CUA that includes
vignette-based utilities. Recommendations are provided on: (A) when to use vignette-based utilities, (B) methods for
developing vignettes, (C) valuing vignettes, (D) use of vignette-based utilities in models, and (E) limitations of vignette
methods.
Keywords: cost-utility analysis, health state utilities, health state vignettes, time trade-off, utility assessment, vignette-based
methods
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Introduction
Health technology assessment (HTA) agencies often prefer that
utilities used to calculate quality-adjusted life years in cost-utility
analyses (CUAs) are derived from generic preference-based mea-
sures (GPBMs) completed by patients in clinical trials.1 For
example, the influential guide from the National Institute for
Health and Care Excellence (NICE) in the United Kingdom in-
dicates a preference for utilities derived via the EQ-5D to maxi-
mize “consistency across appraisals.”2 The guide adds that utilities
derived via other methods may be acceptable when the EQ-5D is
not “available” or “appropriate.” When dimensions of available
GPBMs are not appropriate for a specific medical condition or
treatment, researchers can consider alternative preference-based
measures, including condition-specific preference-based mea-
sures (CSPBMs) or a “bolt-on” approach in which a condition-
specific item is added to a GPBM.3-5 When no preference-based
data from a trial are available, it may be possible to generate
utilities by mapping from a patient-reported outcome measure to
a GPBM.6,7 However, there are situations when no standardized
approach is feasible or appropriate for a specific medical condition
or treatment that must be represented in a CUA. When this occurs,
vignette-based methods are often used to estimate utilities.8,9
In these studies, a vignette is a description of the impact of a
medical condition that is valued in a preference elicitation task to
obtain a utility estimate. Vignettes may describe a medical
condition, its treatment, and its impact on various domains of
health-related quality of life (HRQL). The vignettes may be called
“scenarios,” “health state descriptions,” “health state vignettes,” or
“health states.” For decades, this approach has been used to derive
utilities for a wide range of medical and psychiatric conditions.10-23
Vignette-based utilities are often published and used in CUAs
conducted to inform decision making about healthcare resource
allocation in multiple countries. Although some HTA guidelines do
not explicitly mention the role of vignette-based utilities,2,24 others
list vignette methods as one of the options for estimating utili-
ties.25,26 A substantial portion of CUAs submitted to NICE use util-
ities that deviate from the recommended EQ-5D approach,
including utilities based on vignettes.8,9
Despite the ongoing use of vignette-based methods with po-
tential impact on economic modeling and healthcare resource
allocation, there is no published guidance or review of this
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methodology. Therefore, the purpose of this article is to provide
recommendations for researchers deciding whether to use
vignette-based methods, designing a study, or using resulting
utilities in a CUA. This article includes the following sections: (A)
when to use vignette-based utilities, (B) methods for developing
vignettes, (C) valuing vignettes, (D) use of vignette-based utilities
in models, and (E) limitations of vignette methods.
A. When to Use Vignette-Based Utilities
Before initiating a vignette-based study, it is essential to
consider whether there is justification for this method rather than
generating utilities by having patients complete a preference-
based instrument such as the EQ-5D,27 Health Utilities Index
(HUI),28 or a CSPBM. One advantage of the vignette approach is
that it can be used to estimate utilities for medical conditions and
treatment attributes that may be difficult or impossible to obtain
via preference-based measures, mapping, or published literature.
Five situations in which vignette methods may be useful are
described below and summarized in Table 1.
1. Patients Who Are Difficult to Access
With some groups of patients, it may not be possible to recruit
a large enough sample to complete preference-based measures. A
vignette-based study, with vignettes valued by general population
respondents, may be the only feasible method for estimating
health state utilities needed for a model. For example, vignette
methods are often used to estimate utilities for rare diseases,
where the sample size of any patient data would be insufficient to
represent all disease states required for an economic model. Ex-
amples include beta thalassemia,29 familial chylomicronemia
syndrome,30 hemophilia,23 pemphigus,31 inherited retinal dis-
ease,15 hypophosphatasia,32 and neuroendocrine tumors.33
Patients with debilitating impairment or highly intensified
treatment may also be difficult to access for completion of GPBMs.
Examples include patients who are receiving inpatient psychiatric
treatment, unconscious, in acute phases after stroke,34 or under-
going inpatient chemotherapy or stem cell transplant.35 Some
pediatric samples are also difficult to access for completion of
GPBMs.36,37
2. Isolating the Utility Impact of Specific Attributes
Sometimes, CUAs require utilities representing the impact of a
single symptom, adverse event (AE), or treatment attribute.
Although generic instruments can be sensitive to specific symp-
toms, such as pain, they may not be able to isolate the utility
impact of a single attribute because the scores they yield are
influenced by broader aspects of the patient experience. In
contrast, with the vignette approach, it is possible to isolate the
utility impact of a single attribute. For example, to estimate the
disutility of an AE not captured by a GPBM, utilities can be derived
for 2 vignettes that are identical except for the addition of the AE
Table 1. Situations when vignette-based methods are commonly used to estimate health state utilities.
Situation Brief description Examples of relevant
vignette-based studies
1. Patients who are difficult to
access
With some groups of patients, it may not be possible to recruit a large
enough representative sample to complete preference-based
measures. A vignette study may be the only feasible way to estimate
utilities to represent these health states in a model (eg, rare diseases,









Steen Carlsson et al23
Swinburn et al33
2. Isolating the utility impact
of specific attributes
By keeping all aspects of a vignette constant except for a single
attribute, it is possible to isolate the utility impact of a single
characteristic, such as a symptom, adverse event, or treatment
attribute. Although GPBMs can be sensitive to some specific
symptoms, such as pain, these instruments may not be able to isolate








3. Treatment process utilities Utilities can be used to quantify the impact of treatment process
attributes, such as mode of administration, dose frequency, medical
device attributes, and treatment convenience. A GPBM is unlikely to
be sensitive to utility differences stemming from specific treatment
process attributes. Consequently, process utilities are usually








Steen Carlsson et al23
4. Acute and temporary health
states
Some medical conditions involve flares or exacerbations. It can be
difficult to administer a preference-based measure to patients at the
time of these temporary events. Vignette-based methods can be used
to estimate a disutility in this situation.
Matza et al71
Matza et al30
5. Health states that change
over time
A “path state” vignette can represent a patient proceeding through a
sequence of temporary experiences in a typical course of a medical






AE indicates adverse event; CUA, cost-utility analysis; GPBM, generic preference-based measure.
2 VALUE IN HEALTH - 2021
to one of the health states. The utility difference score between
these 2 otherwise identical vignettes can be attributed entirely to
the AE, and would therefore represent the disutility (ie, utility
decrease) associated with the AE. This approach has been used to
estimate the utility impact associated with a range of patient ex-
periences.16,38-44
3. Treatment Process Utilities
A growing body of research suggests that utility may be
influenced not only by health status, but also by the process of
receiving care.45-48 These “process utilities” quantify the impact of
attributes such as mode of administration, dose frequency, med-
ical device attributes, and aspects of treatment convenience that
may have an impact on patients’ quality of life.16,17,23,49-57 Treat-
ment process usually has less impact on utility than efficacy,
safety, or symptom severity,43 but it is often important to patients.
Furthermore, treatment process could affect treatment adherence,
which can influence outcomes.58-60 Therefore, it may be useful to
include process utilities in some CUAs.
A generic instrument designed to assess overall health status is
unlikely to be sensitive to utility differences stemming from spe-
cific treatment process attributes. Consequently, process utilities
are usually estimated using alternative approaches such as a
preference-based index focused on a specific treatment process,
discrete choice experiments, and most frequently, time trade-off
(TTO) valuation of health state vignettes.45,46,48,61 As with AEs,
the vignette approach can isolate the utility impact of a specific
treatment process attribute by holding all aspects of a health state
constant except for this attribute. Process utilities estimated with
vignettes have been included in CUAs conducted for HTA sub-
missions,38,41,62 and favorable HTA impressions of cost-
effectiveness suggest that these process utilities can be useful
model inputs.63-66
4. Acute and Temporary Health States
Some medical conditions involve flares or exacerbations, and a
CUA assessing the value of treatment for these conditions may
require utilities for these temporary events.67-69 In some clinical
trials, it may be possible to administer a GPBM frequently so that
utility is likely to be assessed at the time of events that are rele-
vant to subsequent economic modeling.69,70 However, when
events are infrequent, it can be challenging to administer a mea-
sure to estimate utilities at the time they occur. In these situations,
the disutility of an acute event can be estimated by valuing vi-
gnettes with and without the acute event. The utility difference
between these 2 vignettes would represent the disutility of the
event. For example, this approach has been used to estimate
quality-adjusted life year decrements of skeletal-related events
associated with bone metastases.71
5. Health States That Change Over Time
Preference-based measures assess utility at the time patients
complete the instrument. To estimate the utility of a health
experience that changes over time, a preference-based measure
would have to be administered at multiple time points corre-
sponding to key health experiences, which can be challenging. To
estimate utilities of a medical condition that changes over time,
one could consider a vignette approach. Vignettes called “path
states” can represent a hypothetical patient proceeding through a
sequence of temporary experiences, including the typical course
of a medical condition and its treatment.29,34,72,73 Respondents
who value the health states are asked to consider the full path
including the duration of time spent in each part. For example, a
recent vignette study was designed to estimate the disutility of a
surgical site infection.74 Because a patient’s condition changes
rapidly after the unexpected infection, it is usually infeasible to
administer measures to patients at multiple precise time points to
capture the utility impact of the full experience. With the vignette
approach, it was possible to estimate a disutility of the full
sequence of events including the infection, antibiotic treatment,
surgical intervention, and gradual resolution of symptoms.
B. Developing Vignettes
Health state vignettes should be developed in the following
steps (Fig. 1).
1. Determine the Number of Vignettes and Level of Detail
in the Vignettes
First, it is necessary to decide which vignettes should be
developed. Like any utility estimation study, it is important to
consider the anticipated CUAs to ensure that the resulting health
state utility values will be useful.68 Model specifications will help
determine the number of vignettes and the required specificity of
each vignette. Sometimes, a general description may be used to
represent a wide range of patients. Other times, more vignettes
may be needed so that greater granularity in patient characteris-
tics can be represented in a CUA.
The number of health states that can be valued by each
respondent depends on the length and complexity of each health
state. Vignette content should be as brief and simple as possible,
while providing the information necessary to understand the
health state. With less information, participants are more likely to
attend to every detail, understand the health state content,
identify the differences among health states, and avoid logical
inconsistencies in utilities. With longer vignettes, respondents are
more likely to skip, ignore, or forget content, possibly resulting in
inconsistent, illogical, or uninformed valuations.
2. Obtain Evidence to Inform Vignette Content
Vignettes must be supported by the best available evidence so
that the resulting utilities can be trusted as reliable estimates.
Ideally, multiple sources of support will be used, and methods for
gathering this information should be thoroughly presented in the
methods sections of publications.
Vignettes should be supported by citations, including pub-
lished scientific literature, information from established medical
organizations (eg, American Diabetes Association), medication
labels, and/or medical device instructions for use. Published
qualitative studies eliciting the patient perspective may be
particularly helpful for drafting vignette language.
Vignettes are often developed based on interviews with in-
dividuals who have insight into the medical condition or treat-
ment, including patients, clinicians, and/or caregivers. Patients can
explain their personal experience in simple language that may
inform the health state descriptions, while highlighting the most
bothersome symptoms. However, some experiences reported by
individual patients may be unusual or unique, and it is necessary
to determine which aspects of a patient’s report are typical rather
than idiosyncratic. Therefore, quotations from individual patients
should be considered in combination with other sources of
information.
Clinicians who see many patients may be the most common
source of vignette support because they can describe the typical
patient experience based on the range of patients they have
treated. Physicians are often interviewed, but other types of cli-
nicians may have more direct contact with patients, leading to
-- 3
greater insight into the patient experience. For example, with
some types of chemotherapy, oncology nurses may spend more
time with patients than the treating physicians. In some situa-
tions, however, clinicians may not be able to report the broad
impact of a condition or treatment across all domains of HRQL due
to their focus on clinical aspects of disease. If there are areas of
disease impact that might be unfamiliar to clinicians, patient in-
terviews may be a useful way to fill these gaps.
A relatively small number of clinicians are required to describe
health states focusing on objective content, such as procedures for
using medical devices.17 Two may be sufficient to confirm that
vignette descriptions match the typical patient experience. Health
states with more subjective content (eg, symptoms, AEs) usually
require more clinicians (perhaps 4-8). It may also be necessary to
talk to clinicians from multiple specialties. For instance, for vi-
gnettes describing diverse AEs associated with antiretroviral
treatment, input was gathered from a cardiologist, nephrologist,
and several infectious disease specialists.42 The number of clini-
cians needed to support a set of health states also depends on the
medical condition. For rare conditions, clinicians may not have
experience treating patients across the range of severity repre-
sented in vignettes.
Clinicians may be interviewed multiple times. The first
round of interviews can be conducted to gather information
before developing health states, and subsequent discussions
can continue throughout health state development until all
clinicians agree that the vignettes accurately represent the
typical patient experience. When clinicians disagree, a group
meeting by teleconference is often helpful for reaching
consensus.
An empirical approach is to derive vignette statements from
quantitative data such as an outcome measure in a clinical
trial.75-77 For example, 1 study included 2 vignettes representing
adults with attention-deficit/hyperactivity disorder categorized
as treatment responders or nonresponders.78 Health state de-
scriptions were adapted from items on patient-completed rating
scales (eg, “you have problems organizing tasks and activities”).
The 2 health states were differentiated based on the response
options most frequently selected by each patient group as indi-
cated by a pooled analysis of clinical trial data (eg, symptoms
occurred “once in a while” with “minimal consequences” for
responders and “often” with “real consequences” for non-
responders). This empirical support provides evidence that the
health states are a reasonable representation of the target
population.
A newer method for assessing the patient perspective is to
analyze qualitative data from online patient discussion forums.42
This approach provides unique insight into the patient
Figure 1. Suggested good practices for development of health state vignettes.
1. Determine the number of vignettes that will be developed, along with the expected level of 
detail.  These decisions should be based on anticipated modeling needs, while considering  
feasibility of the eventual valuation task..
2. Obtain evidence to inform vignette content.  Vignettes must be supported by the best  
available evidence.  Possible sources of support include:
• Publicly available citations including published scientific literature, information from 
established medical organizations, medication labels, and/or medical device 
instructions for use
• Qualitative interviews (or group discussions) with individuals who have insight into 
the relevant medical condition or treatment (e.g., patients, clinicians, caregivers)
• Quantitative data (e.g., patient-reported outcome measures in clinical trials)
• Qualitative analysis of social media data such as online patient discussion forums
3. Draft the health state descriptions.  General principles include:
• Vignettes should be designed to maximize comprehension (e.g., brief descriptions,  
simple language, avoid medical jargon) 
• Vignettes should represent the typical patient experience
• Vignettes should be designed to facilitate comparison between health states with 
parallel structure when appropriate  
• Supplemental materials such as images, videos, and medical devices may be used to 
provide respondents with a more accurate understanding of the health states
• Avoid uncertainty in health states as much as possible
• Consider advantages and disadvantages of naming the disease in the health state (i.e.,
 the disease label)
• Format vignettes to maximize comprehension and reduce error in the valuations (e.g., 
bullet points, large clear font, generous spacing, headings, colors, bolding, shading)
4. Refine the vignettes: The initial draft should be edited and refined based on two sources of 
information.  
• Clinicians and/or patients should review the draft health states to confirm that they 
clearly and accurately represent the typical patient experience
• The vignettes and utility valuation methods should be tested in a pilot study to assess 
clarity and comprehension of the health states, as well as the number of vignettes each 
participant can value
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perspective expressed outside the research or clinical context. This
methodology can efficiently capture rich qualitative data from
large patient samples, although results should be interpreted with
caution because accuracy of clinical diagnosis is uncertain, and the
online discussions may not focus on the issues that are most
relevant for vignette development.
When articles reporting vignette-based studies are sub-
mitted for publication at peer reviewed journals, reviewers
should carefully attend to the sources of evidence used to
support the vignette content. If this evidence is not clearly
presented, clarification and additions should be requested for
inclusion in a revised article. If the evidence is insufficient,
the vignettes cannot be trusted as a reasonable representation
of the medical condition, and the manuscript should not be
published. The types of evidence described above are
summarized in Table 2.
Table 2. Suggested information to be included in publications of vignette-based utility estimation studies.
Section Details
Introduction  Brief background on the medical condition and its treatment
 Justification for using vignette-based methods, including reasons why GPBMs completed by patients would not be
sensitive, appropriate, or feasible
Methods  Description of evidence used to develop the health states. Evidence may include several of the following sources of
information:
B Citations of relevant published literature
B Clinician interviews (specify clinician’s experience relevant to the health state descriptions and interview methods)
B Patient interviews (specify demographic/clinical characteristics and interview methods)
B Caregiver interviews (specify relationship to patient)
B Quantitative data (eg, patient-reported outcome measures in clinical trials)
B Qualitative coding of social media data such as online patient discussion forums (specify data source and coding
methods)
 Description of the health states, including domains and formatting
 Methods for validating and refining vignettes
B Presenting vignettes to experts (eg, clinicians, patients) and making edits based on their feedback
B Pilot study in which health states are valued in utility elicitation tasks with the target population, which may be either
patients or general population respondents
 Utility interview procedures
 Population used to elicit utility values (including recruitment and sample size)
 Interview setting (eg, in-person individual interviews, group administration, or online utility elicitation)
B Introductory tasks (eg, visual analogue scale or ranking of health states)
B Order of health state presentation
B Utility elicitation procedures: the choices presented to respondents, the ordering of the choices (eg, ping-pong
approach), justification for the time horizon (eg, 10 years), intervals between choices (eg, number of years/months for
TTO; percentages for standard gamble)
B Approach for valuing health states perceived as worse than dead
B Plans for addressing logical inconsistencies or unusual patterns of data during the interviews (eg, methods for
carefully querying unusual responses to confirm that they represent the respondent’s true preference, rather than a
mistake)
B Scoring for both positive and negative utilities
 Statistical analysis procedures including descriptive statistics, utility comparisons, subgroup comparisons, plans for
addressing logical inconsistencies, negative utility scores, and/or outliers
Results  The results that will be presented vary depending on the purpose of the study. At a minimum, mean utilities are typically
presented (with SD or 95% confidence intervals). The following results may also be included:
B Mean utility difference scores for comparisons between health states
B Parameters from regression models of utility scores based on the health states and covariates
B Significance testing of differences between health state utility scores
B Frequency of differentiation between health states (ie, the percentage of respondents who had different utility scores
for a pair of health states)
B Frequency of negative utility scores for each health state
B Results of introductory tasks (eg, ranking the health states), which can be a useful way to check validity of the utilities
B Frequency of logical inconsistencies
B Subgroup comparisons (eg, utilities for subgroups categorized based on demographic or clinical variables)
Discussion  Summary of key preferences
 Potential use of the utilities (eg, how might the utilities be included in a model)
 Comparisons to relevant utilities derived in previous studies
 Limitations of the methodology and the specific vignettes
Supplemental
material
 Complete health state text should be provided. If this material is too long to be included in the article text, it may be
presented as an appendix or as supplemental material available online. Because any word or phrase in a vignette can
have an impact on the resulting utility value, it is important that reviewers, readers, and modelers using the utilities have
access to the full vignettes
 If formatting is unique, a formatted health state may be presented
 Other materials used to help participants understand the vignettes (eg, images used in vignettes, screenshots from
videos, or photos of medical devices that were used to clarify health state content)
CUA indicates cost-utility analysis; GPBM, generic preference-based measure; SD, standard deviation; TTO, time trade-off.
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3. Draft the Health State Descriptions
The structure of vignettes varies across studies, but there are
some general principles that should be considered when drafting
vignettes.
Comprehension
Vignettes should be designed to maximize comprehension. It is
essential that respondents can understand the health states, recall
the content, and identify differences between health states. When
vignettes are too long, respondents tend to focus only on a few
details because it is difficult to remember all the information.
Therefore, vignettes should be as brief as possible. Furthermore,
descriptions must be presented in simple language that avoids
medical jargon so that they can be understood by almost all re-
spondents. Shorter, simpler health states are easier to compre-
hend and value accurately in a preference-based task, thus
ensuring that the resulting utilities are based on a good under-
standing of health state content, while minimizing error and
logical inconsistencies.
Typical patient experience
A health state vignette cannot represent the full range of pa-
tient experiences with any disease or treatment. Instead, vignettes
should describe the typical patient experience, and the resulting
utility will represent this “midpoint” health state. Therefore,
health states should include the most common attributes, while
omitting unusual patient experiences that could clutter the
vignette and obscure the main points.
Comparability between vignettes
Often, the most important results from a vignette-based study
are the differences between health state utilities, which represent
differences in preference. Thus, health states should be designed
to facilitate comparison between health states with parallel
structure and statements to ensure that participants can recognize
the differences.
Supplemental materials
Supplemental materials may be used to help respondents un-
derstand vignettes. For some medical conditions (eg, dermato-
logic), images may help clarify health state content. Videos may
help clarify observable symptoms or procedures.17,76,79,80 For
health states describing medical devices, interviewers may be able
to demonstrate using the devices.17 For visual acuity, devices have
been used to simulate visual impairment.81 When presenting
health states that change over time, a timeline depicting the series
of events can add clarity.74
Avoid uncertainty
Whenever possible, health states should avoid statements with
uncertainty, such as “you may feel fatigued” or “you might require
treatment.” Respondents’ interpretations of these uncertain
statements will vary. While some respondents optimistically as-
sume the best possible outcome, others expect more negative
outcomes. If participants each make their own unique assump-
tions when valuing health states, this will increase variability and
error, making it difficult to know exactly which health state the
utilities represent. Sometimes, it may be necessary to include
some uncertainty to reflect the patient experience accurately, such
as living with the risk of serious AEs.42 However, this should be
done with caution because any uncertainty interferes with inter-
pretation of results and reduces confidence in utility scores.
Labeling the medical condition
Previous research has examined the effects of naming (ie, la-
beling) the disease in a health state. There is some evidence that
naming the disease can influence utility,82 although other studies
have reported that the disease label did not affect results.83,84
Some diseases such as cancer or human immunodeficiency virus
may be associated with preconceptions, fear, stigma, or bias. In
these situations, it may be important to omit the label. In other
studies, naming the disease may help ensure health states are
clear and unambiguous. Therefore, when designing vignettes, re-
searchers should consider the advantages and disadvantages of
including the label.
Formatting
Careful formatting can help respondents understand the health
states and reduce error in the valuations. Vignettes are often
presented as a series of individual cards or pages that can be or-
dered by the respondents (Fig. 2). Bullet point lists are easier to
read and comprehend than long paragraphs. Font should be clear
and large with sufficient space between bullets to maximize
readability. Different colored borders for each vignette can help
respondents distinguish between a set of health states. De-
scriptors should be grouped according to concept, and headings
for each category can be provided to help respondents understand
the organization of the concepts (eg, symptoms, impact, treat-
ment, AEs). Background colors (perhaps light gray or yellow) can
be used to show that specific sections either do or do not vary
across a set of health states. Differences between vignettes can be
underlined or bolded to help respondents recognize and
remember them. However, the use of too much color and
emphasis can be distracting and confusing, and the vignette
formatting should be assessed in a pilot study.
4. Refine the Vignettes
After the initial draft, health states require editing and refining
based on 2 sources of information. First, clinicians and/or patients
should review the draft health states so that edits can be made
based on their feedback. Generally, health states should not be
considered final until all these experts agree that they clearly and
accurately represent the typical patient experience. If experts
disagree, a discussion among multiple clinicians may be arranged
to reach consensus.
Second, vignettes and utility valuation methods should be
tested in a pilot study to ensure that respondents understand the
health states and can distinguish between them in a logical way.
Health states can be edited based on respondents’ feedback. A
pilot study is also useful for determining how many health states
are feasible. If it appears that participants cannot provide reliable
valuations for a set of health states because there are too many,
each participant can be randomly assigned to value a subset, but
this strategy reduces the sample size for each vignette (unless the
sample size is increased to compensate). If the pilot is conducted
in multiple phases, health states can be edited throughout so that
the final pilot participants value the final set of health states.
The pilot sample size depends on the complexity of the health
states. A sample of 20 respondents is usually sufficient, but fewer
may be enough to reach saturation (ie, the point when no new
information is provided) if the vignettes are straightforward. More
participants might be needed if health states are complicated or if
the researchers are uncertain about the optimal utility assessment
method. After the pilot, the vignettes should be ready for use in a
larger valuation study.
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Figure 2. Example of a formatted health state vignette.*
A
Description†
• You have migraine.‡  This is an unpredictable disorder that causes  
disabling headaches and other associated symptoms.  
• You are treated with a medication that reduces the number and  
duration of migraine episodes. 
• Because of the treatment, you have fewer headaches.  
Treatment§
• You are treated with one injection every 4 weeks.  
• You give yourself this injection at home.
• You can inject yourself in the thigh or abdomen.
Symptoms||
• You now have migraine headaches 5 to 8 days each month.  Each  
headache lasts about 2 to 6 hours. 
• At the beginning of each episode, you feel tired and you notice that 
you have neck discomfort. 
• Each episode includes a very painful headache, usually on one side of 
your head.  The pain is severe and throbbing, and it becomes worse 
with movement. 
• During each episode, it is hard for you to concentrate.  You feel like 
you have “brain fog.” 
• During many of these episodes, you feel like you are going to be sick 
(nausea), and you feel uncomfortably sensitive to light and sound.
• After each migraine episode, you feel tired and worn out.
Impact¶
• On days with a migraine, it is difficult for you to perform everyday 
tasks.
• For example, when you are affected by migraines, it is difficult to 
concentrate and be productive at home, work, or school.  
• If you have children, it is difficult to care for them on days with a 
migraine. 
• When you have a migraine, you would prefer to stay at home.
* This vignette, called “health state A,” was used in a published study.16 Several aspects of the formatting 
were designed to help respondents understand the health states and the differences between health 
states. For example, each health state had different colored borders, and descriptions were presented in 
short bullet points with space between each bullet to maximize readability.  
†
Descriptors were grouped with headings to help respondents understand the organization of the concepts
(e.g., description, treatment, symptoms…).  
‡
Health states in this study included the name of the medical condition (migraine) because it was 
expected that participants would recognize migraine based on the symptoms.  Therefore, omitting this 
label could have raised questions or caused confusion.  For some conditions that may be associated with 
biased preconceptions, such as cancer or HIV, it is often preferable to omit the label to avoid bias.
§
The purpose of this set of health states was to evaluate preferences for various treatment 
administration options (i.e., to estimate treatment process utilities).  The “Treatment” section had a 
shaded yellow background to indicate that this section varied across health states while the other 
sections remained constant.  Differences between vignettes can also be underlined or bolded to help 
respondents recognize and remember them.  
||
Symptoms were described based on interviews with clinicians who reported the language patients 
commonly use to describe typical migraine symptoms.  These symptom descriptions were also 
supported by published literature.
¶
Descriptions of impact are included so that migraine symptoms and treatment can be interpreted in the 
context of overall functioning, including impact on usual activities and social functioning.
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C. Valuing Vignettes
After developing the vignettes, they are valued in preference
elicitation tasks, most commonly TTO or standard gamble, to es-
timate a utility for each health state.85-88 If necessary, aspects of
the utility assessment methods can be varied (eg, the TTO time
horizon) to ensure that the methods are appropriate for the health
states and sufficiently sensitive to detect true differences in pref-
erence. When determining valuation methods for a vignette study,
it is useful to consider comparability with GPBMs preferred by
HTA authorities. For example, if utilities will be used in a NICE
submission, vignettes can be valued using TTO methods similar to
those used to derive scoring tariffs for the EQ-5D (3L or 5L).89
Whereas valuation studies for GPBMs are conducted to derive a
scoring function, the primary results of vignette studies are usu-
ally the mean health state utilities. Regression models may also be
run to understand the influence of each health state and relevant
covariates on utility.18,39,44,90 The analysis approach should be
specified a priori, including methods for addressing logical in-
consistencies, outliers, and negative utility scores. To help readers
interpret findings, publications should include all details that
modelers and reviewers would need to evaluate the utilities
(Table 2), including justification for using the vignette-based
approach.
D. Use of Vignette-Based Utilities in Models
Vignette-based utilities may be used like other utilities in
CUAs.68 Modelers can use the actual utility value (eg, 0.80 on the
utility scale anchored to 0 and 1), but it is also common to use
vignettes to identify utility difference scores for adjusting utilities
from a standardized instrument. For example, a recently published
model used an EQ-5D value of 0.785 for type 2 diabetes as a
baseline utility, but added a utility benefit of 0.03 for patients
using a new glucose monitoring approach.91 The difference score
of 0.03 was estimated in a vignette-based study.17 To avoid
double-counting the utility impact of an attribute when using this
approach, it is important to consider whether the attribute rep-
resented in the vignettes also has an impact on the GPBM utility.
One cautious approach is to apply these vignette-based utility
adjustments in sensitivity analyses.68 A CUA can first be run
without the adjustments, yielding a base case incremental cost-
effectiveness ratio. Then, the CUA can be re-run as a sensitivity
analysis with the vignette-based utility adjustments, yielding a
different incremental cost-effectiveness ratio. With this approach,
HTA reviewers can consider results with and without the vignette
utilities.
E. Limitations of Vignette Methods
Before conducting a vignette study or using vignette-based
utilities in a CUA, researchers must consider the limitations.
First, although vignettes may be rigorously developed based on
the best available evidence, the utilities are not directly provided
by patients living in the health states. Therefore, the utilities
represent preferences for the vignette, which can differ from the
health status of actual patients with the condition. While a
vignette-based utility may be a useful approximation of patient
HRQL, consistency with utilities generated using preference-based
measures with patients is uncertain.
Second, the validity of the utilities depends on the accuracy
and level of detail of the health state descriptions, which cannot
include all possible aspects of the patient experience. Even a well-
developed vignette could inadvertently omit details that are
important to some patients. Third, because a vignette cannot
represent the full range of patient experiences within a health
state, the utilities may underestimate the variability associated
with most medical conditions.
Fourth, vignette-based methods are not standardized, and
procedures for developing and valuing vignettes vary across
studies. There is also no standardization regarding the content of a
health state description. If vignettes focus on a specific treatment
without providing broader context of the medical condition and
HRQL, respondents may overestimate the importance of minor
attributes without considering other aspects of health. To mini-
mize these focusing effects and increase comparability across
studies, vignettes should include broader aspects of HRQL (eg,
functioning, usual activities).
Finally, vignettes can lead to biased responses if they empha-
size some issues while downplaying others. Therefore, when
interpreting results of vignette studies or using the resulting
utilities in a CUA, it is important to review the content of the vi-
gnettes to ensure that they provide an accurate and unbiased
description of the health state. The best way to avoid these limi-
tations is to consider modeling needs early in a drug development
program and include a GPBM in clinical trials to gather utilities
from patients.69
Conclusion
Despite HTA agency preferences for utilities derived from
GPBMs completed by patients, there will always be new medical
treatments with outcomes, treatment processes, or AEs that could
affect quality of life but cannot be captured by standardized in-
struments. When patient-completed preference-based measures
are not feasible or appropriate for obtaining utilities needed for a
CUA, a vignette-based approach may be the only available option.
Like all inputs in a CUA, vignette-based utilities can affect model
results, which inform subsequent decision making and healthcare
resource allocation. Therefore, vignette utility studies must be
well designed, carefully conducted, clearly reported, and inter-
preted with appropriate caution.
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